Kairos Pharma, Ltd. (KAPA) Reports 17.7-Month PFS in ENV-105 Trial

What happened

Kairos Pharma reported that ENV-105 plus apalutamide produced a median PFS of 17.7 months versus 2 months for apalutamide alone in a Phase 2 mCRPC trial, with P=0.0008. The trial will now focus on first-line therapy after enzalutamide in a larger group.

Confirmed

Global impact / market context

A large survival gap could make ENV-105 a more valuable treatment candidate, but the release lacks patient counts and trial-design details. The next larger study must confirm the result before investors can treat it as a durable clinical and commercial advantage.

Analyst inference

Kairos is a clinical-stage company, so its value rests on trial data rather than current sales. Positive Phase 2 results can draw investor attention, but without confirmed larger-group data or regulatory progress, the finding remains a preliminary signal.

Analyst inference

What to watch

1. The next trial focus is first-line therapy after enzalutamide in a larger group; watch whether that study enrolls and reports as planned. Confirmed
2. Watch for the company to disclose patient counts and trial-design details for the Phase 2 study, which the release did not provide. Proposed
3. Watch whether larger-group results preserve the 17.7-month median PFS advantage, since confirmation would support the treatment's potential. Analyst inference

Evidence

• Original source link unavailable